Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Edgewise Therapeutics enters the final stretch before its November 5 earnings print with the stock down 8% over the past month, a put/call ratio that has been running well above its recent norm, and two confirmed activists on its 13D register, a setup that frames this week's quiet drift as anything but routine.
The clearest shift in positioning has been in the options market. The put/call ratio has dropped back to 0.77 from levels above 0.87 across much of last week, but that recent run was itself a dramatic reversal. Through September the ratio hovered near 0.10, deep call-heavy territory. By late September it surged above 0.87, suggesting a rapid rotation into downside protection. At 0.77 today the ratio has eased slightly, but remains well above the 20-day mean of 0.51 and close to its 52-week high of 0.92. That is a meaningful change in how options traders are positioned on this name. Short interest, by contrast, tells a calmer story. At 9.05% of the free float it is material but has barely moved, down less than 1% on the week. Borrowing is almost frictionless, with cost to borrow at 0.49% and availability at over 1,000% of outstanding short interest, meaning shares to borrow are plentiful relative to demand. There is no squeeze dynamic here, and no evidence that the options shift is being driven by a crowded short trying to cover.
The Street remains mostly constructive, though not uniformly so. JP Morgan raised its target to $60 and Goldman Sachs lifted to $36 in August, the two in pointed disagreement about how much the Phase 2 EDG-7500 data is worth. The majority of recent moves have been upgrades or target increases: Evercore, Oppenheimer, Guggenheim, RBC, and HC Wainwright have all raised targets since June, with most landing in the $51 to $59 range against a current price of $39.57. Goldman's $36 target is the outlier, below the current price and reflecting a Neutral rating, a signal that at least one major house sees the stock as fairly valued or stretched on a risk-adjusted basis. The mean target of $52.62 implies roughly 33% upside from here. On factor scores, EPS momentum is exceptional, in the 98th percentile on a 30-day basis and 100th on 90 days, while the short score rank of 27 reflects that, despite a 9% SI reading, this stock does not screen as a heavily pressed short.
The bull case rests on the June Phase 2 CIRRUS-HCM Part D readout, which showed broad gains across hemodynamics, biomarkers, symptoms, and function for EDG-7500 in both obstructive and non-obstructive HCM, with no heart-failure events and no LVEF drops below 50% in the reported cohort. Bears point to the single-program risk: the valuation is built almost entirely on replicating those results in larger Phase 3 cohorts, and the company has no commercial revenue. The $1.55 billion sale of the sevasemten and muscular dystrophy portfolio to Servier materially changed the financial picture, fully funding EDG-7500 development through potential approval, but the clinical execution risk remains undiluted. Wikipedia attention for the stock registered a z-score of 3.5 against its own 90-day history as of late September, pointing to a spike in retail interest around the time of the options shift.
The ownership register adds another layer of interest. OrbiMed Advisors holds 14.3% and has filed a Schedule 13D, making it a confirmed activist on the register. Novo Holdings, the investment arm of the Novo Nordisk Foundation, also holds a 13D position at just under 5%. Both filings are event-driven disclosures around the 5% threshold, and positions are as last disclosed, so stakes may have changed. Among other large holders, Paradigm BioCapital added 2.85 million shares in the June quarter while RA Capital trimmed by just over 2 million. Baker Bros cut its stake roughly in half, filing an updated 13G at 3.4% compared to 6.9% previously. FMR (Fidelity) entered the top register with a fresh 13G, owning just over 5%. The composition of the holder base, dominated by specialist healthcare funds and a Novo Holdings strategic position, is consistent with a stock whose story is primarily being told in biotech specialist circles rather than generalist hands.
Prior earnings prints have been negative: the August 2026 release produced a 3.3% single-day decline and a 4.0% five-day loss, while the May print fell 4.5% on the day and 8.1% over the following week. Both were pre-CIRRUS Part D. The next print on November 5 is the first quarterly update since that readout and since the Servier deal closed, so the market's reaction function may be different. With 28 days to go, the options positioning shift from near-zero put coverage to a PCR approaching its annual high is the number to watch as the print approaches.
See the live data behind this article on ORTEX.
Open EWTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
